MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, IPSC had -$11,254K decrease in cash & cash equivalents over the period. -$25,846K in free cash flow.

Cash Flow Overview

Change in Cash
-$11,254K
Free Cash flow
-$25,846K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from pipe, net of issua...
    • Sale of fixed maturity securitie...
    • Depreciation
    • Others
Negative Cash Flow Breakdown
    • Acquisition of fixed maturity se...
    • Accrued expenses and other liabi...
    • Change in fair value of continge...
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net income (loss)
-21,645 -19,171 -34,428 44,019
Depreciation
3,004 3,550 3,129 6,422
Non-cash operating lease expense (benefit)
412 427 517 968
Stock based compensation
1,445 1,300 892 4,648
Impairment
-0 6,763 -
Accretion of investments
211 349 507 1,501
Change in fair value of contingent liabilities
1,818 4,919 -240 -145
Gain on reduction in lease liability due to lease termination
-0 1,395 -
Deferred tax (benefit) expense
--73 --
Prepaid expenses and other assets
62 -1,321 -585 -436
Operating lease liability
-786 -1,399 -1,232 -2,347
Deferred revenue
-0 0 -109,164
Accounts payable
-1,625 2,157 -591 -4
Accrued expenses and other liabilities
-3,956 1,079 443 -5,837
Security deposit
-20 ---
Net cash used in operating activities
-25,262 -16,077 -25,584 -62,215
Acquisition of property and equipment
584 -139 195 792
Acquisition of fixed maturity securities, available for sale
140,691 15,599 11,023 24,552
Sale of fixed maturity securities, available for sale
28,660 37,821 35,889 85,813
Net cash provided (used in) by investing activities
-112,615 22,361 24,671 60,469
Proceeds from issuance of common stock and espp
202 53 0 120
Proceeds from pipe, net of issuance costs
126,421 ---
Net cash provided by financing activities
126,623 53 0 120
Net decrease in cash, cash equivalents, and restricted cash
-11,254 6,337 -913 -1,626
Cash, cash equivalents and restricted cash, beginning of period
65,011 58,674 61,213 -
Cash, cash equivalents and restricted cash, end of period
53,757 65,011 58,674 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from pipe, net ofissuance costs$126,421K Proceeds from issuance ofcommon stock and espp$202K Net cash provided byfinancing activities$126,623K Net decrease incash, cash...-$11,254K Canceled cashflow$126,623K Sale of fixedmaturity securities,...$28,660K Depreciation$3,004K Stock basedcompensation$1,445K Non-cash operating leaseexpense (benefit)$412K Net cash provided(used in) by investing...-$112,615K Canceled cashflow$28,660K Net cash used inoperating activities-$25,262K Canceled cashflow$4,861K Acquisition of fixedmaturity securities,...$140,691K Acquisition of property andequipment$584K Net income (loss)-$21,645K Accrued expenses andother liabilities-$3,956K Change in fair value ofcontingent liabilities$1,818K Accounts payable-$1,625K Operating lease liability-$786K Accretion of investments$211K Prepaid expenses andother assets$62K Security deposit-$20K

Century Therapeutics, Inc. (IPSC)

Century Therapeutics, Inc. (IPSC)